WALTHAM, MA, June 11, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received positive feedback from the U.S. Food and Drug Administration (“FDA”) regarding the requested packaging for EyeGate’s Ocular Bandage Gel (“OBG”)…
WALTHAM, Mass., Feb. 07, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced today that Stephen From, Eyegate’s President and Chief Executive Officer, will present at the 2018 BIO CEO & Investor Conference being held…
WALTHAM, MA, September 9, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that EyeGate’s President and Chief Executive Officer, Brian M. Strem, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C.…
Top-Line Data from First-in-Human Pilot Study Expected by Year-End 2016 WALTHAM, Mass., November 17, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that, following a pre-submission meeting with the U.S.…
WALTHAM, Mass., May. 11, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced financial results for the three-month period ended March 31, 2018, and provided an update on recent corporate and operational activities.…
Novel Approach Offers Eye Care Practitioners Delivery Alternative for Post-Operative Therapeutic Regimens LAVAL, QUEBEC and WALTHAM, MA – FEBRUARY 21, 2017 – Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) and EyeGate Pharmaceuticals, Inc. (Nasdaq: EYEG) (“EyeGate”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders…
WALTHAM, Mass., July 10, 2015 (GLOBE NEWSWIRE) — Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that it has entered into an exclusive, worldwide licensing agreement with a subsidiary of Valeant Pharmaceuticals…
WALTHAM, Mass., May 04, 2017 – EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that it has submitted an Investigational Device Exemption (IDE) for the lead product in its cross-linked thiolated carboxymethyl hyaluronic…
WALTHAM, Mass., January 14, 2016 — Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG, EYEGW) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the Noble…
WALTHAM, Mass., January 24, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the Noble Financial…
